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Abstract
Background: The clinical benefit of determining the status of HER-2/neu amplification in breast
cancer patients is well accepted. Although immunohistochemistry (IHC) is the most frequently
used method to assess the over-expression of HER-2 protein, fluorescent in-situ hybridization
(FISH) is recognized as the "gold standard" for the determining of HER-2/neu status. The greatest
discordance between the two methods occurs among breast tumors that receive an indeterminate
IHC score of 2+. More recently, a real-time polymerase chain reaction (PCR) assay using the
LightCycler® has been developed for quantifying HER-2/neu gene amplification. In this study, we
evaluated the sensitivity and specificity of a commercially available LightCycler assay as it compares
to FISH. To determine whether this assay provides an accurate alternative for the determination
of HER-2/neu  status, we focused primarily on tumors that were deemed indeterminate or
borderline status by IHC.
Methods: Thirty-nine breast tumors receiving an IHC score of 2+ were evaluated by both FISH
and LightCycler® technologies in order to determine whether quantitative real-time PCR provides
an accurate alternative for the determination of HER-2/neu status.
Results: We found a high concordance (92%) between FISH and real-time PCR results. We also
observed that 10% of these tumors were positive for gene amplification by both FISH and real-time
PCR.
Conclusion: The data show that the results obtained for the gene amplification of HER-2/neu by
real-time PCR on the LightCycler® instrument is comparable to results obtained by FISH. These
results therefore suggest that real-time PCR analysis, using the LightCycler®, is a viable alternative
to FISH for reassessing breast tumors which receive an IHC score of 2+, and that a combined IHC
and real-time PCR approach for the determination of HER-2 status in breast cancer patients may
be an effective and efficient strategy.
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Background
Gene amplification and over-expression of the HER-2/neu
gene, also known as c-erbB-2 or ERBB2, is frequently
observed (approximately 25–30%) in human breast can-
cer [1]. The HER-2/neu gene, which is a member of the
epidermal growth factor receptor (HER) family, is located
on chromosome 17q11.2-12 [2] and encodes a 185 kDa
transmembrane tyrosine kinase receptor protein.
Considered to play a role in the biologic behavior or
pathogenesis of human breast cancer, the amplification of
the HER-2/neu gene is now regarded as an established pre-
dictive [3] and prognostic [4] marker for breast cancer,
particularly for the management of advanced breast can-
cer. Both node-positive and node-negative breast cancer
patients whose tumors exhibit HER-2/neu amplification,
have a poor prognosis, an increased risk of recurrence and
a high risk of disease-related death showing overall
shorter survival rates [5-7,7-10].
However, the major interest in HER-2/neu amplification
lies in its utility as a predictive marker of responsiveness
to therapy [11] primarily, the response of breast cancer
patients to chemotherapy, hormonal therapy (antiestro-
gens) and therapeutic anti-HER-2 antibodies. Tumors
with amplification of this oncogene are less responsive to
CMF (cyclophosphamide, methotrexate, and 5-fluorour-
acil) adjuvant chemotherapy regimens than those with a
normal levels of the gene product [12]. Conversely, HER-
2/neu  amplification is a useful marker to identify the
patients who are most likely to benefit from high doses of
doxorubicin (Adriamicin) therapy [13-15]. Patients with
HER-2/neu  gene amplification/over-expression are less
responsive to tamoxifen therapy [16-18]. However, the
HER-2/neu status is mainly used for identifying patients
with advanced breast cancer who may benefit from the
therapy with anti-HER-2 antibody trastuzumab/Hercep-
tin® (Genetech, San Francisco, CA) a humanized murine
monoclonal antibody which has been shown to be effec-
tive in prolonging survival in patients with receptor posi-
tive metastatic breast carcinoma [19].
While the clinical benefit of determining the status of
HER-2/neu  amplification/over-expression is clearly
accepted, several methods for assessment and quantifica-
tion of HER-2/neu gene alteration have been used in the
search of an accurate, quantitative, widely applicable in
clinical setting and cost-effective assay.
Immunohistochemistry (IHC) is most frequently used to
assess the over-expression of HER-2 protein. It is an indi-
rect method of measuring gene amplification and is based
on the ability of antibodies to identify HER-2 proteins
expressed by fixed cells in frozen or paraffin embedded
tissue sections. In general, IHC is carried out on paraffin
embedded tissues using standard laboratory equipment
and therefore is the method of choice for most clinical
laboratories. However, IHC analysis relies on subjective
interpretation of staining intensity and extent of tumor
cells within a section in order to assign an expression score
of 0/1+ (regarded as IHC negative) or 2+/3+ (regarded as
IHC positive).
Determination of HER-2/neu  amplification by Fluores-
cent in-situ hybridization (FISH) strategies is an alternate
method of choice. Whereas IHC detects the over-expres-
sion of the HER-2 protein, FISH is a direct method to
detect HER-2/neu gene amplification. However, FISH is
more time consuming to perform, relatively expensive
and requires specialized equipment. Nevertheless, the
accuracy of this technique means that FISH assessment is
accepted as the "gold standard" for the determination of
HER-2/neu status in paraffin embedded breast tumors.
Polymerase chain reaction (PCR)-based assays are able to
determine both changes in HER-2/neu gene number and
expression [20]. Real-time PCR analysis of DNA offers a
precise quantitative analysis of gene amplification. The
advantage of this technique is that it is simple, conven-
ient, non-radioactive and rapid so that it is highly suitable
for a routine clinical laboratory. No expertise beyond
accurate and aseptic pipetting technique is required. How-
ever, results from real-time PCR quantitative assays can be
affected by contamination of the tumor sample with
nucleic acids from non-tumor surrounding tissues. This
problem can be reduced by using laser-assisted microdis-
section, or if not available, by carefully outlining the
tumor area on the slide and using only the tumor tissue
for analysis.
The evaluation of HER-2/neu status at the mRNA level by
reverse-transcription PCR (RT-PCR) has also been pro-
posed [20,21] but the use of formalin-fixed paraffin-
embedded tissue for this purpose is problematic as the
RNA is often extensively degraded. Therefore, the use of
RT-PCR is limited to availability of frozen tissue.
Chromogenic  in situ hybridization (CISH) is a more
recently introduced method for detecting HER-2/neu
amplification [22]. CISH makes use of the in situ hybridi-
zation technology but also takes advantage of the chro-
mogenic signal detection of IHC. With CISH, a DNA
probe is detected using a simple IHC-like peroxidase reac-
tion and positive signals can be detected with the ordinary
light microscope. One advantage of CISH is that the assay
is one quarter the cost of FISH and can be used when flu-
orescent microscopy is not available. However CISH, like
IHC, relies on subjective interpretation and the utility of
some low/high amplified CISH results are sometime in
question.BMC Clinical Pathology 2006, 6:2 http://www.biomedcentral.com/1472-6890/6/2
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To date, the FDA has approved two methods [23] for the
selection of cancer patients for receiving Herceptin® (Tras-
tuzumab) therapy: IHC and FISH. In practice, both tech-
niques are used in conjunction. IHC assay is used as an
initial screening assay to identify clearly negative or posi-
tive cases. The FISH assay is then used subsequently in
those cases where IHC status is indeterminate (2+ IHC
positive cases). This sequential strategy avoids the high
cost and relatively longer time delay of using the FISH
assay in all cases. More recently, a LightCycler HER-2/neu
DNA Quantification kit (Roche Molecular Biochemicals,
Mannheim, Germany) is currently commercially available
and a real-time PCR LightCycler assay has been developed
for HER-2/neu evaluation. Advances in PCR technology
using the real-time fluorescent monitoring capabilities of
the LightCycler have the potential to enable relatively
inexpensive, rapid and accurate quantification of gene
amplification [24]. The evaluation of the quantitative real
time PCR assay for HER2/neu is the focus of this study.
Our objective was to evaluate the specificity and sensitiv-
ity of the LightCycler real-time PCR assay as it compares
to FISH, focusing primarily on tumors that are indetermi-
nate or borderline HER-2 status by IHC.
Methods
Tissue samples
Between January 2001 and December 2004, 1673 breast
tumors were routinely examined by IHC analysis for HER-
2 protein overexpression at the Immunopathology Labo-
ratory at the Health Science Center, Winnipeg, Manitoba.
The tumor samples were fixed, processed and paraffin
embedded according to standard protocols [25]. Border-
line samples (scored +2 by IHC) consisted of approxi-
mately 10% of the total number of breast tumor samples
tested.
Representative Paraffin blocks of 39 randomly selected
primary breast tumor samples ranked +2 by IHC were
obtained from the Immunopathology Laboratory. FISH
and Real-Time PCR analysis were conducted by the
Molecular Diagnostic Pathology Laboratory. For real-time
PCR analysis, tumor areas with a minimum 100 tumor
cells/cm2 and minimal 'contaminating' normal breast tis-
sue were outlined on the cover glass slip with a permanent
marker. The outlined areas were scraped into eppendorf
tubes for DNA extraction.
This study was approved by the Pathology Access Com-
mittee for Tissues (PACT) and the Research Ethics Board
at the University of Manitoba.
Immunohistochemistry (IHC) analysis
IHC analysis of the HER-2 protein expression was carried
out in histologic sections of breast cancer specimens using
the HercepTest (DAKO, CA, USA). The HercepTest was
approved by the FDA (September, 1988) for selection of
women with breast cancer in order to receive trastuzumab
humanized monoclonal antibody therapy. Six µm thick
tissue sections of the paraffin-embedded blocks were cut,
mounted on silane-coated slides, deparaffinized, heat-
treated for antigen retrieval [26] and immunostained. The
heat treatment involved heating in pressure cooker in 10
mmol/L citrate buffer for 40 minutes and tissue sections
were then cooled. The immunostaining process was car-
ried out using the DAKO Autostainer Universal Staining
System according to the instructions of the manufacturer
(DAKO, Corp). Briefly, tissue sections were treated with
peroxidase-blocking reagent for 5 minutes, rinsed and
treated with rabbit anti-human HER-2 primary antibody
for 30 minutes. The sections were then rinsed and treated
for 30 minutes with secondary goat anti rabbit antibody
and horseradish peroxidase and, following rinsing, incu-
bated in diaminobenzidine for 10 minutes. The sections
were removed from the Autostainer and counterstained
with hematoxylin and mounted in Permount. Membrane
staining was interpreted as HER-2 protein overexpression
using a bright-field Olympus microscope according to an
established scoring system [20] as 0, 1+, 2+ and 3+ as fol-
lows: 0 indicating absence of staining, 1+ indicating the
lowest level of detectable staining and/or non-homoge-
nous weak staining, 2+ indicating moderate homogenous
membrane staining and 3+ indicating intense homoge-
nous membrane staining. Immunostaining was consid-
ered positive when more than 10% of all cells had 2+ or
3+ staining intensity.
FISH analysis
FISH analysis was carried out using the Vysis LSI HER-2/
neu SpectrumOrange and CEP 17 SpectrumGreen Dual
Color DNA probe kit (Vysis PathVysion®, Abbot Laborato-
ries, IL) according to the manufacturer's instructions. The
locus specific identifier (LSI) HER-2/neu DNA probe is a
190-Kb SpectrumOrange fluorescent-labeled probe that
specifically hybridizes to the HER-2/neu gene locus,
17q11.2-q12. The chromosome enumeration probe
(CEP) 17 is a 5.4-Kb SpectrumGreen fluorescent labeled
DNA probe specific for the alpha satellite DNA sequence
at the centromeric region of chromosome 17, 17p11.1-
q11.1.
HER-2/neu gene copy level was determined by FISH anal-
ysis of paraffin-embedded tissue sections as a ratio
between the HER-2/neu gene copies and the chromosome
17 centromere copies (Vysis, Inc.). This approach excludes
polysomy of chromosome 17 as a source of increased
HER-2/neu gene copy number.
The 6 µm thick tissue sections on slides were deparaffin-
ized in xylene, followed by dehydration with absolute eth-BMC Clinical Pathology 2006, 6:2 http://www.biomedcentral.com/1472-6890/6/2
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anol, air-dried and pre-treated using the Vysis Paraffin
Pretreatment Kit I (Vysis, Inc.). Following pre-treatment,
the hybridization process was performed at 37°C for 14–
18 hours (overnight) and the nuclei were then counter-
stained with 4'-6'-diamidino-2'-phenylindole (DAPI).
Enumeration of HER-2/neu and CEP 17 probe signals was
performed under fluorescence microscopy with a 100-
watt mercury lamp at 1000X magnification using a Zeiss
Axiophot fluorescent microscope with triple bands filters.
Scoring was restricted to cancer cells by demarcation of
the tumor area on the H&E stained slides by two breast
cancer pathologists (PW, WO). In each specimen, 60 non-
overlapping nuclei were counted. The green signals for
centromere 17 and the orange signals for HER-2/neu gene
were recorded and the ratio calculated for each slide.
According to the manufacturer's guidelines, nuclei with-
out signals or only one-color signals or nuclei with insuf-
ficient DAPI counter-stain to determine the nuclear
Table 1: Comparison of HER-2/neu status assessed by FISH and Real-Time PCR in 39 breast cancer samples deemed 2+ by IHC
Sample number FISH Real-Time PCR
CEP 17 HER-2 Ratio Status Ratio Status
1 1.83 1.83 1.00 - 1.33 -
2 1.45 1.60 1.10 - 0.48 -
3 1.18 1.23 1.04 - 0.65 -
4 1.35 1.27 0.94 - 1.3 -
5 1.48 1.75 1.18 - 1.5 -
6 1.37 1.37 1.00 - 1.74 -
7 2.40 3.21 1.34 - 0.66 -
8 1.88 1.73 0.92 - 1.35 -
9 6.22 5.85 0.94 - 1.46 -
10 1.77 1.75 0.99 - 1.62 -
11 1.28 1.28 1.00 - 1.49 -
12 1.72 1.68 0.98 - 1.52 -
13 1.53 1.50 0.98 - 1.42 -
14 1.80 1.78 0.99 - 1.43 -
15 3.30 3.22 0.98 - 1.18 -
16 2.47 2.45 0.99 - 1.59 -
17 1.73 1.82 1.05 - 0.41 -
18 1.70 1.73 1.02 - 1.53 -
19 1.83 1.93 1.05 - 0.35 -
20 3.03 3.55 1.17 - 1.58 -
21 1.97 1.55 0.79 - 1.65 -
22 1.68 1.72 1.02 - 1.60 -
23 1.40 1.20 0.86 - 1.39 -
24 1.27 1.80 1.42 - 1.77 -
25 1.20 1.18 0.98 - 1.68 -
26 1.07 1.07 1.00 - 0.44 -
27 1.10 1.08 0.98 - 0.76 -
28 1.98 2.40 1.21 - 1.49 -
29 1.85 2.58 1.39 - 1.96 -
30 2.70 3.22 1.19 - 1.76 -
31 1.95 1.97 1.01 - 1.84 -
32 4.17 6.85 1.64 - 1.67 -
33 1.92 2.00 1.04 - 2.07 +
34 1.77 7.13 4.03 + 1.83 -
35 1.93 4.92 2.55 + 1.51 -
36 1.92 6.77 3.53 + 3.91 +
37 1.77 16.70 9.44 + 11.10 +
38 2.00 5.87 2.94 + 2.09 +
39 2.00 8.15 4.08 + 2.39 +
CEP 17 = mean/cell of the chromosome 17 centromere probe signals HER-2 = mean/cell of the HER-2/neu probe signals
FISH Ratio = the ratio between HER-2 and CEP 17
Real-Time PCR Ratio = the normalized ratio between HER-2 and the reference gene (gastrin)
"+" = positive, "-"=negative. Cases (8%) that were discordant between PCR and FISH assays are highlighted.BMC Clinical Pathology 2006, 6:2 http://www.biomedcentral.com/1472-6890/6/2
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border were not scored. A ratio of HER-2/neu to chromo-
some 17 copy number ≥ 2.2 was considered positive and
a ratio < 1.8 was considered negative for HER-2/neu
amplification. The scoring of slides, which presented a
ratio between 1.8 and 2.2, was re-evaluated.
Real-Time Quantitative PCR Analysis of HER-2/neu Gene 
Amplification
The DNA extraction was performed using the High Pure
PCR Template Preparation Kit (Roche).
Real-Time PCR Analysis was performed using the LightCy-
cler (Roche Molecular Biochemicals, Mannheim, Ger-
many) and the LightCycler HER-2/neu Quantification Kit
(Roche Molecular Biochemicals, Mannheim, Germany).
The gastrin gene was used as the reference housekeeping
gene. A 112-bp fragment of the Her-2/neu gene and a 133-
bp fragment of the gastrin gene were amplified during the
PCR reaction. The simultaneously quantification of the
HER-2/neu gene and the reference gene that serves both as
control for DNA integrity and as a reference for relative
quantification was achieved by using different labeled
hybridization probes (Red-705 for the HER-2/neu  and
Red-640 for the gastrin specific oligonucleotide) which
allow dual color detection in the same capillary. Five µl
(approximately 1 µg) of each sample of the template DNA
was mixed with the ready-to-use primers and hybridiza-
tion probes, enzyme solution (Taq DNA polymerase) and
dNTP reaction mix included in the kit in a final volume of
20 µl. The pre-incubation and denaturation of the tem-
plate DNA were performed at 95°C for 12 minutes. This
was followed by amplification of the target DNA through
45 cycles of denaturation at 95°C for 10 seconds, anneal-
ing at 58°C for 10 seconds and elongation at 72°C for
another 10 seconds. The specimens were then cooled to
40°C. Samples were analysed in duplicates. The LightCy-
cler HER-2/neu Quantification Kit contained a calibrator
DNA provided to generate a calibration curve. The cross-
ing point data for the HER-2/neu and the reference gene
were determined and exported into Relative Quantifica-
tion Software that allowed the calculation of the HER-2/
gastrin normalized ratio. A ratio target gene/reference
gene = 2.0 was considered positive for HER-2/neu gene
amplification.
Statistical analysis
Statistical analysis was performed using GraphPad
PRISM®, Version 3.02. The concordance between Real
Time LyghtCycler PCR and FISH assays were analysed by
a Fisher's exact probability test (Table 2), the cut-off point
to assign negative and positive status for each method
being established as previously described in Material and
Methods. The correlation between the two tests was estab-
lished by calculating the Spearman correlation coefficient.
Results
As FISH is currently the "gold standard" method for eval-
uation of HER-2/neu amplification we wanted to examine
the performance of the LightCycler Real Time PCR assay
as measured against FISH assay in IHC borderline cases.
Thirty-nine breast tumor samples that scored 2+ for HER-
2 protein expression by IHC analysis were selected for this
study. Our results (summarized in Table 1) show that of
the 39 tumors, 32 (82%) were scored negative for HER-2/
neu gene amplification and 4 (10%) were scored positive
by both PCR and FISH methods, the overall correlation
between FISH and real-time PCR results being 92% (36 of
39 tumors). Of the remaining 3 tumors, 1 was positive by
real-time PCR and negative by FISH and 2 were positive
by FISH and negative by PCR (Fig. 1).
The results of our study are summarized in the contin-
gency table (illustrated in Table 2) generated by categoriz-
ing the results according to the cut-off points described in
Material and Methods for each test. Statistical analysis
confirmed the 92% concordance between the HER-2/neu
statuses assessed by the 2 methods (p < 0.0009, two-sided
Fisher's test). The Spearman rank correlation coefficient
was r = 0.45 at 95% confidence interval (p = 0.0038, two-
tailed Spearman correlation).
Discussion
Thirty percent of breast cancer patients exhibit overexpres-
sion of the HER-2 gene and the HER-2/neu status corre-
lates with the response to both specific receptor targeted
Concordance between FISH and real-time PCR in IHC 2+  cases (92%) Figure 1
Concordance between FISH and real-time PCR in IHC 2+ 
cases (92%).
1
2
3
4
82% FISH-/PCR-
10% FISH+/PCR+
5% FISH+/PCR-
3% FISH-/PCR+
+ = positive
- = negative
Table 2: Contingency table showing the breast tumors included 
in our study categorized according to the cutoff points 
established for each test (as described in Material and Methods).
FISH\PCR -+
-3 2 2
+1 4BMC Clinical Pathology 2006, 6:2 http://www.biomedcentral.com/1472-6890/6/2
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therapy as well as other treatments. It has therefore been
recommended that routine screening for HER-2/neu
amplification should be performed as part of the evalua-
tion of each new diagnosed case of breast carcinoma [27].
Whereas a lack of assessment of the HER-2/neu  status
deprives breast cancer patients from beneficial treatment,
a false positive diagnosis of gene amplification could lead
to an unnecessary expensive therapy with multiple possi-
ble side effects, including cardiac dysfunction [28].
In order to establish the best strategy to assess the HER-2/
neu status, numerous studies have compared the results of
the two FDA approved assay methods. The discordance
between the accuracy of HER-2 protein as determined by
IHC and gene amplification as determined by FISH has
sparked much debate in the last few years. Some authors
have reported a concordance rate as high as 91% [29] or
88% [30], but claim a weak concordance between the two
methods when the HercepTest score is 2+, such as a 35%
concordance [30]. Similarly, 75% of the discordant cases
(positive by IHC and negative by FISH) had a HercepTest
score of 2+ [31]. On the other hand, in a large recently
published study [32], only 0.7% of the IHC negative
tumors were found to be positive by FISH and 5.9% IHC
3+ tumors were FISH negative so that there was a very
good correlation between the HER-2/neu status assessed
by FISH and IHC in 0, 1+ as well as 3+ tumors. Therefore
it has been proposed that the 2+ score, as defined in the
guidelines for the FDA-approved HercepTest, should not
be used as a criterion for trastuzumab therapy unless con-
firmed by FISH [33].
Our study was therefore focused predominantly on this
borderline 2+ IHC category. Using a real-time PCR quan-
titative assay, we found a 92% concordance between FISH
and real-time PCR results in breast tumors previously
assessed with moderate increased HER-2 protein expres-
sion (2+) by IHC. We also found that 10% of these tumors
were positive for gene amplification by both FISH and
real-time PCR, and the remaining 90%, determined to be
negative. The high concordance (92%) between the FISH
and real-time PCR results as well as the discordance
between both of these 2 methods with the IHC assay, sug-
gests that real-time PCR is more accurate in determining
the patients who are true candidates for trastuzumab ther-
apy. A similarly high concordance between FISH and real-
time PCR was previously reported [34,35]. In addition,
the same authors [34] reported that the observed 92%
concordance rate later increased to 98% following the
incorporation of laser-assisted microdissection into the
real time PCR protocol, and they were then able to reclas-
sify the FISH positive, PCR negative specimens to FISH
positive, PCR positive.
We also found that two cases negative by FISH, exhibited
polysomy of chromosome 17. Interestingly, in these two
tumor samples, IHC detected the increased HER-2 protein
expression but could not discriminate between true over-
expression and polysomy of chromosome 17. We recog-
nize that polysomy of chromosome 17 can occur in a
detectable frequency. Therefore, for quantitative real time
PCR assays, consideration should be given to the intro-
duction of a second control gene that is located at a dis-
tance away from the amplifiable region and able to detect
numerical abnormalities of chromosome 17. The deter-
mination of the copy number of chromosome 17 might
be helpful in differentiating breast cancer patients with
polysomy of chromosome 17 and those that overexpress
the of HER-2 protein and may help identify subgroups of
patients that probably have genetic and clinical differ-
ences [21,36].
It is also important to note that the prevalence of cancer
cells in scraped tissue used for DNA extraction or the
inclusion of microdissection strategies, will have an
impact on the real-time PCR results. Thus, samples previ-
ously deemed PCR negative could be truly PCR positive,
when microdissection of the pure tumor tissue was
employed.
The results of our present study demonstrate that there
can be discordance between the most commonly used
assay method (IHC) and other methods of assessing the
HER-2 status. Specifically in IHC borderline positive
cases, our data suggest that real-time PCR possesses a high
potential to enhance accuracy in clinical settings for diag-
nosis of true trastuzumab therapy candidates. These data
need to be confirmed by a larger study as well as a clinical
study designed to compare how the HER-2/neu  status
assessed by FISH and real-time PCR correlates with the
response to Herceptin therapy.
Conclusion
The results obtained by real-time PCR for the amplifica-
tion of HER-2/neu gene in breast tumors were comparable
with results obtained by FISH and suggests that real-time
PCR using the LightCycler is a viable alternative to FISH
for evaluating tumors deemed indeterminate by IHC. A
combined IHC and real-time PCR approach for determin-
ing HER-2/neu amplification in breast cancer patients may
be an effective and efficient strategy.
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